The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Acquisition of epithelial–mesenchymal transition and cancer stem cell phenotypes is associated with activation of the PI3K/Akt/mTOR pathway in prostate cancer radioresistance
Open accessAbstract
Radioresistance is a major challenge in prostate cancer (CaP) radiotherapy (RT). In this study, we investigated the role and association of epithelial-mesenchymal transition (EMT), cancer stem cells (CSCs) and the PI3K/Akt/mTOR signaling pathway in CaP radioresistance. We developed three novel CaP radioresistant (RR) cell lines (PC-3RR, DU145RR and LNCaPRR) by radiation treatment and confirmed their radioresistance using a clonogenic survival assay. Compared with untreated CaP-control cells, the CaP-RR cells had increased colony formation, invasion ability and spheroid formation capability (P<0.05). In addition, enhanced EMT/CSC phenotypes and activation of the checkpoint proteins (Chk1 and Chk2) and the PI3K/Akt/mTOR signaling pathway proteins were also found in CaP-RR cells using immunofluorescence, western blotting and quantitative real-time PCR (qRT-PCR). Furthermore, combination of a dual PI3K/mTOR inhibitor (BEZ235) with RT effectively increased radiosensitivity and induced more apoptosis in CaP-RR cells, concomitantly correlated with the reduced expression of EMT/CSC markers and the PI3K/Akt/mTOR signaling pathway proteins compared with RT alone. Our findings indicate that CaP radioresistance is associated with EMT and enhanced CSC phenotypes via activation of the PI3K/Akt/mTOR signaling pathway, and that the combination of BEZ235 with RT is a promising modality to overcome radioresistance in the treatment of CaP. This combination approach warrants future in vivo animal study and clinical trials.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Jemal, A., Siegel, R., Xu, J., & Ward, E. (2010) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20073 · Cited by 12,596
The Epithelial-Mesenchymal Transition Generates Cells with Properties of Stem Cells
Mani, S. A., Guo, W., Liao, M.-J., Eaton, E. N., Ayyanan, A., Zhou, A. Y., Brooks, M., Reinhard, F., Zhang, C. C., Shipitsin, M., et al. (2008) · Cell · doi:10.1016/j.cell.2008.03.027 · Cited by 8,672
Glioma stem cells promote radioresistance by preferential activation of the DNA damage response
Bao, S., Wu, Q., McLendon, R. E., Hao, Y., Shi, Q., Hjelmeland, A. B., Dewhirst, M. W., Bigner, D. D., & Rich, J. N. (2006) · Nature · doi:10.1038/nature05236 · Cited by 6,379
EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer
Singh, A., & Settleman, J. (2010) · Oncogene · doi:10.1038/onc.2010.215 · Cited by 2,545
Linkage of ATM to Cell Cycle Regulation by the Chk2 Protein Kinase
Matsuoka, S. (1998) · Science · doi:10.1126/science.282.5395.1893 · Cited by 1,322
Maira, S.-M., Stauffer, F., Brueggen, J., Furet, P., Schnell, C., Fritsch, C., Brachmann, S., Chène, P., De Pover, A., Schoemaker, K., et al. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-0017 · Cited by 1,134
Fillmore, C. M., & Kuperwasser, C. (2008) · Breast Cancer Research · doi:10.1186/bcr1982 · Cited by 1,033
Ansieau, S., Bastid, J., Doreau, A., Morel, A.-P., Bouchet, B. P., Thomas, C., Fauvet, F., Puisieux, I., Doglioni, C., Piccinin, S., et al. (2008) · Cancer Cell · doi:10.1016/j.ccr.2008.06.005 · Cited by 715
Isolation and in vitro expansion of human colonic stem cells
Jung, P., Sato, T., Merlos-Suárez, A., Barriga, F. M., Iglesias, M., Rossell, D., Auer, H., Gallardo, M., Blasco, M. A., Sancho, E., et al. (2011) · Nature Medicine · doi:10.1038/nm.2470 · Cited by 709
The mesenchymal cell, its role in the embryo, and the remarkable signaling mechanisms that create it
Hay, E. D. (2005) · Developmental Dynamics · doi:10.1002/dvdy.20345 · Cited by 641
EMT as the ultimate survival mechanism of cancer cells
Tiwari, N., Gheldof, A., Tatari, M., & Christofori, G. (2012) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2012.02.013 · Cited by 512
Jeter, C. R., Liu, B., Liu, X., Chen, X., Liu, C., Calhoun-Davis, T., Repass, J., Zaehres, H., Shen, J. J., & Tang, D. G. (2011) · Oncogene · doi:10.1038/onc.2011.114 · Cited by 394
Kong, D., Li, Y., Wang, Z., & Sarkar, F. H. (2011) · Cancers · doi:10.3390/cancers30100716 · Cited by 346
Self-citationNanog signaling in cancer promotes stem-like phenotype and immune evasion
Noh, K. H., Kim, B. W., Song, K.-H., Cho, H., Lee, Y.-H., Kim, J. H., Chung, J.-Y., Kim, J.-H., Hewitt, S. M., Seong, S.-Y., et al. (2012) · Journal of Clinical Investigation · doi:10.1172/jci64057 · Cited by 194
What Dose of External-Beam Radiation is High Enough for Prostate Cancer?
Eade, T. N., Hanlon, A. L., Horwitz, E. M., Buyyounouski, M. K., Hanks, G. E., & Pollack, A. (2007) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2007.01.008 · Cited by 163
New Therapies for Castration-Resistant Prostate Cancer: Efficacy and Safety
Beltran, H., Beer, T. M., Carducci, M. A., de Bono, J., Gleave, M., Hussain, M., Kelly, W. K., Saad, F., Sternberg, C., Tagawa, S. T., et al. (2011) · European Urology · doi:10.1016/j.eururo.2011.04.038 · Cited by 163
Zhou, Y., Liu, J.-Y., Li, J., Zhang, J., Xu, Y., Zhang, H.-W., Qiu, L.-B., Ding, G., Su, X., Mei-Shi, et al. (2011) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2011.06.1956 · Cited by 148
The role of nutraceuticals in the regulation of Wnt and Hedgehog signaling in cancer
Sarkar, F. H., Li, Y., Wang, Z. P., & Kong, D. (2010) · Cancer and Metastasis Reviews · doi:10.1007/s10555-010-9233-4 · Cited by 130
Self-citationEmerging roles of radioresistance in prostate cancer metastasis and radiation therapy
Chang, L., Graham, P., Hao, J., Bucci, J. A., Cozzi, P. J., Kearsley, J. H., & Li, Y. (2014) · Cancer and Metastasis Reviews · doi:10.1007/s10555-014-9493-5 · Cited by 129
Self-citationZhu, L., Hu, Y., Yang, C., Xu, X., Ning, T., Wang, Z., Ye, J., & Liu, L. (2012) · Laboratory Investigation · doi:10.1038/labinvest.2012.8 · Cited by 93
Role of the EpCAM (CD326) in prostate cancer metastasis and progression
Ni, J., Cozzi, P. J., Duan, W., Shigdar, S. L., Graham, P., John, K. H., & Li, Y. (2012) · Cancer and Metastasis Reviews · doi:10.1007/s10555-012-9389-1 · Cited by 87
Self-citationHao, J., Madigan, M. C., Khatri, A., Power, C. A., Hung, T., Beretov, J., Chang, L., Xiao, W., Cozzi, P. J., Graham, P., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0040716 · Cited by 83
Self-citationChk2-mediated G2/M cell cycle arrest maintains radiation resistance in malignant meningioma cells
Gogineni, V. R., Nalla, A. K., Gupta, R., Dinh, D. H., Klopfenstein, J. D., & Rao, J. S. (2011) · Cancer Letters · doi:10.1016/j.canlet.2011.08.022 · Cited by 83
Coen, J. J., Bae, K., Zietman, A. L., Patel, B., Shipley, W. U., Slater, J. D., & Rossi, C. J. (2010) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2010.06.047 · Cited by 71
Chk1 knockdown confers radiosensitization in prostate cancer stem cells
WANG, X., Ma, Z., XIAO, Z., Liu, H., Dou, Z., Feng, X., & Shi, H. (2012) · Oncology Reports · doi:10.3892/or.2012.2068 · Cited by 66
Smith, L., Qutob, O., Watson, M. B., Beavis, A. W., Potts, D., Welham, K. J., Garimella, V., Lind, M., Drew, P. J., & Cawkwell, L. (2009) · Neoplasia · doi:10.1593/neo.09902 · Cited by 55
Josson, S., Sharp, S. M., Sung, S.-Y., Johnstone, P. A. S., Aneja, R., Wang, R., Gururajan, M., Turner, T., Chung, L. W. K., & Yates, C. C. (2010) · Journal of Oncology · doi:10.1155/2010/232831 · Cited by 39
CD44 is a biomarker associated with human prostate cancer radiation sensitivity
Xiao, W., Graham, P., Power, C. A., Hao, J., Kearsley, J. H., & Li, Y. (2011) · Clinical & Experimental Metastasis · doi:10.1007/s10585-011-9423-7 · Cited by 36
Self-citationProstate Cancer and Parasitism of the Bone Hematopoietic Stem Cell Niche
Yu, C., Shiozawa, Y., Taichman, R. S., McCauley, L. K., Pienta, K. J., & Keller, E. T. (2012) · Critical Reviews in Eukaryotic Gene Expression · doi:10.1615/critreveukargeneexpr.v22.i2.50 · Cited by 34
Wang, L., Chen, H., Liu, F., Madigan, M. C., Power, C. A., Hao, J., Patterson, K., Pourgholami, M. H., O’Brien, P. M., Perkins, A. C., et al. (2010) · Cancer Letters · doi:10.1016/j.canlet.2010.09.013 · Cited by 30
Self-citationChao, H., Wang, L., Hao, J., Ni, J., Chang, L., Graham, P., Kearsley, J. H., & Li, Y. (2012) · Cancer Letters · doi:10.1016/j.canlet.2012.08.035 · Cited by 29
Self-citation
Cited by
Targeting cancer stem cell pathways for cancer therapy
Yang, L., Shi, P., Zhao, G., Xu, J., Peng, W., Zhang, J., Zhang, G., Wang, X., Dong, Z., Chen, F., et al. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-0110-5 · Cited by 1,906
Lee, S. Y., Jeong, E. K., Ju, M. K., Jeon, H. M., Kim, M. Y., Kim, C. H., Park, H. G., Han, S. I., & Kang, H. S. (2017) · Molecular Cancer · doi:10.1186/s12943-016-0577-4 · Cited by 578
mTOR Signaling in Cancer and mTOR Inhibitors in Solid Tumor Targeting Therapy
Tian, T., Li, X., & Zhang, J. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20030755 · Cited by 576
Cancer stem cells (CSCs) in cancer progression and therapy
Najafi, M., Farhood, B., & Mortezaee, K. (2019) · Journal of Cellular Physiology · doi:10.1002/jcp.27740 · Cited by 573
Cancer stem cells: advances in knowledge and implications for cancer therapy
Chu, X., Tian, W., Ning, J., Xiao, G., Zhou, Y., Wang, Z., Zhai, Z., Tanzhu, G., Yang, J., & Zhou, R. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01851-y · Cited by 553
Metadata
- Authors
- Chang, L., Graham, P. H., Hao, J., Ni, J., Bucci, J., Cozzi, P. J., Kearsley, J. H., & Li, Y.
- Venue
- Cell Death & Disease
- Published
- 2013-10-24
- Volume
- 4
- Issue
- 10
- Pages
- e875-e875
- ISSN
- 2041-4889 (ISSN-L)
- OpenAlex
- W2067311782
- Cited by
- 377
- References
- 31
- FWCI
- 13.31
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.